> Intarcia pulled in $200 million for its Phase III exenatide minipump designed to deliver the drug to diabetes patients over the course of a year. Story
> The European Medicines Agency gave Alnylam ($ALNY) a positive opinion regarding the orphan status of the company's ALN-TTRsc RNAi drug for patients with transthyretin-mediated amyloidosis. Release
> Particle Sciences entered a development agreement with Actavis ($ACT) for an unnamed generic product using one of Particle's many delivery technologies. Release
> Ablative Solutions won FDA clearance for its Peregrine infusion catheter designed to deliver drugs directly to the perivascular layer surrounding the blood vessels. Release
> Biolight filed an IND with the FDA for a Phase I/IIa study of its glaucoma implant with controlled release of latanaprost. Release